Galera Therapeutics Inks $11M
Galera Therapeutics Inc., a developer of drugs targeting oxygen metabolic pathways in cancer, fibrosis and other human diseases, has raised $11 million Series A funding. The round is co-led by New Enterprise Associates and Novartis Venture Fund and includes participation from Correlation Ventures. The money will be used to expand clinical development.
11 December 2012•4 mins read
